NeoStem Forges Ahead in Its Plan to Open Adult Stem Cell Collection Centers in Key Locations that Can Serve as Hubs to Service Clients Nationwide
Chester Amedia, Jr. MD, FACP, is the Founder and President of CelVida LLCand has had extensive business and patient care experience in the fields ofdisease management and extracorporeal therapy. "We are thrilled to be partof what many believe to be an emerging "Stem Cell Revolution" and have chosento strategically align with NeoStem to provide individuals looking for aproactive approach to their future medical care the opportunity to have theirstem cells collected and preserved for use in the future in the event ofmedical need," stated Dr. Amedia. "It is estimated that by 2017 there will beas many as 2 million annual procedures that will include stem cell basedtherapies for diabetes, orthopedic injuries, cardiovascular disease,inflammatory diseases, among others."
"We are thrilled to be working with such an accomplished physician who hasdemonstrated success in building a flourishing medical business. We believethat patient specific stem cell collection and storage one day will be viewedas being as routine as securing health insurance. We continue to see anabundance of evidence in the scientific literature as data from clinicaltrials supports the proposition that autologous adult stem cell therapies areemerging as an important measure in repairing degenerated, damaged anddiseased tissue (the three "Ds" of aging)," said Robin Smith, MD, CEO ofNeoStem.
About CelVida LLC
CelVida was organized to develop a network of personal self-care centersin key metropolitan markets around the country. The CelVida network intendsto make the simple process of stem cell collection and storage available toindividuals proactively seeking healthcare options that embrace newtechnologies.
About NeoStem, Inc.
NeoStem is managing a network of adult stem cell collection centers,enabling people (through its proprietary technology) to donate and store theirown (autologous) stem cells when they are young and/or relatively healthy fortheir personal use in times of future medical need. The Company has alsorecently entered into research and development through the acquisition of aworldwide exclusive license to technology to identify and isolate VSELs (verysmall embryonic-like stem cells), which have been shown to have severalphysical characteristics that are generally found in embryonic stem cells.
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995. Forward-lookingstatements reflect management's current expectations, as of the date of thispress release, and involve certain risks and uncertainties. The Company'sactual results could differ materially from those anticipated in theseforward-looking statements as a result of various factors. Factors that couldcause future results to materially differ from the recent results or thoseprojected in forward-looking statements include the "Risk Factors" describedin the Company's periodic filings with the Securities and Exchange Commission.Contact: NeoStem, Inc. Robin Smith, Chief Executive Officer T: 212-584-4180 E: firstname.lastname@example.org www.neostem.com
SOURCE NeoStem, Inc.
You May Also Like